Roche Pegasys better at hep B?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche plans to file its pegylated interferon Pegasys for hepatitis B next year, based on the results of a head-to-head Phase III study showing Pegasys to be more effective than lamivudine in difficult-to-treat variant hepatitis B. The highly statistically significant results showed that 42.9% of patients on Pegasys monotherapy met the primary endpoint of reduction in viral load below 20,000 copies/mL compared to 29.3% of lamivudine patients. Additionally, combination use of Pegasys and lamivudine reduced hepatitis B viral DNA in 44.1% of patients, "demonstrating that the addition of lamivudine to Pegasys does not improve the treatment outcome," Roche reports. Data were presented at the American Association for the Study of Liver Diseases annual meetin
You may also be interested in...
Recent Approvals In Brief
Bristol’s Abilify adds bipolar maintenance indication; AstraZeneca’s Atacand receives approval for heart failure in advance of advisory committee review; other recent approvals in brief
Gilead Emtriva hep B data
Preliminary results of Gilead's Phase III hepatitis B study for Emtriva (emtricitabine) show a 62% improvement in the primary endpoint of liver histology, compared to 25% for placebo (p<0.001). Data from the 48-week, 248-patient study will be presented at a major medical meeting in 2004. Gilead hopes to have guidance from FDA for a regulatory plan by the middle of 2004. The firm previously indicated that it expects to submit a hepatitis B NDA for the nucleoside reverse transcriptase inhibitor in late 2004. Roche also is planning a 2004 hepatitis B submission for its peg-interferon product Pegasys (1Pharmaceutical Approvals Monthly Nov. 1, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”